These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 35454923)

  • 21. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Atwa SM; Odenthal M; El Tayebi HM
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
    Rallis KS; Makrakis D; Ziogas IA; Tsoulfas G
    World J Clin Oncol; 2022 Jun; 13(6):448-472. PubMed ID: 35949435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview.
    van Doorn DJ; Takkenberg RB; Klümpen HJ
    Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33374927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving therapeutic strategies for advanced hepatocellular carcinoma.
    Qureshi A; Michel M; Lerner J; Dasanu CA
    Expert Opin Pharmacother; 2021 Dec; 22(18):2495-2506. PubMed ID: 34252328
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan.
    Taketomi A
    JMA J; 2021 Jul; 4(3):241-245. PubMed ID: 34414318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
    Lee YH; Tai D; Yip C; Choo SP; Chew V
    Front Immunol; 2020; 11():568759. PubMed ID: 33117354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
    Hwang SY; Lee SL; Liu H; Lee SS
    Liver Cancer; 2024 Jun; 13(3):246-255. PubMed ID: 38894810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
    Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
    Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review.
    Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma.
    Foy V; McNamara MG; Valle JW; Lamarca A; Edeline J; Hubner RA
    Curr Oncol; 2023 Sep; 30(9):8665-8685. PubMed ID: 37754543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frontline therapy for advanced hepatocellular carcinoma: an update.
    Akce M; El-Rayes BF; Bekaii-Saab TS
    Therap Adv Gastroenterol; 2022; 15():17562848221086126. PubMed ID: 35432597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
    Giraud J; Chalopin D; Blanc JF; Saleh M
    Front Immunol; 2021; 12():655697. PubMed ID: 33815418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review.
    He X; Peng Y; Zhou Z; Li W
    Front Oncol; 2022; 12():784224. PubMed ID: 35372050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.
    Biglow L; Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():22. PubMed ID: 34917675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
    Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.